Scientific Sessions 2024  /  Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations  /  Discussant: ATTR-Specific Medication in Dual Pathology Aortic Stenosis and Transthyretin Cardiac Amyloidosis
Logo

American Heart Association

  171
  0

Final ID:

Discussant: ATTR-Specific Medication in Dual Pathology Aortic Stenosis and Transthyretin Cardiac Amyloidosis

  • Nativi-nicolau, Jose  ( Mayo Clinic , Jacksonville , Florida , United States )
    • Author Disclosures:
    Jose Nativi-Nicolau: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alnylam:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations

Monday, 11/18/2024 , 09:45AM - 11:00AM

Featured Science

More abstracts on this topic:
Discussant: Danon Disease Phase 1 RP-A501

Gillmore Julian, Taylor Matthew, Adler Eric

Danon Disease Phase 1 RP-A501 Results: The First Single-Dose Intravenous Gene Therapy with Recombinant Adeno-Associated Virus (AAV9:LAMP2B) for a Monogenic Cardiomyopathy

Greenberg Barry, Coggins Matthew, Schwartz Jonathan, Rossano Joseph, Taylor Matthew, Colan Steven, Adler Eric, Ricks David, Yarabe Paul, Battiprolu Pavan, Shah Guarav, Patel Kinnari

More abstracts from these authors:
Red Flags in New Onset HFpEF that Should Raise Suspicion for Cardiac Amyloidosis

Alexander Kevin, Nativi-nicolau Jose, Raymer David

Evolving Baseline Risk in Patients With Transthyretin Amyloid Cardiomyopathy: A Systematic Literature Review of Clinical Trials

Masri Ahmad, Nativi-nicolau Jose, Wright Richard, Betts Marissa, Lavoie Louis, Shree Aiswarya, Hennum Liana, Tamby Jean-francois, Falvey Heather, Dev Sandesh

You have to be authorized to contact abstract author. Please, Login
Not Available